Publications by authors named "Tom Van de Casteele"

Claim this Profile
O
Opportunities and challenges with decentralized trials in Neuroscience.
Hans Ulrich Burger, Tom Van de Casteele, Khadija Rerhou Rantell, Patricia Corey-Lisle, Nikolaos Sfikas

Biom J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.
Nadja Bredo Rasmussen, Christina Deligianni, Casper Emil Christensen, William Kristian Karlsson, Haidar Muhsen Al-Khazali, Tom Van de Casteele

J Headache Pain· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.
Nadja Bredo Rasmussen, Christina Deligianni, Casper Emil Christensen, William Kristian Karlsson, Haidar Muhsen Al-Khazali, Tom Van de Casteele

J Headache Pain· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody.
Kristof Van Kolen, Thomas J Malia, Clara Theunis, Rupesh Nanjunda, Alexey Teplyakov, Tom Van De Casteele

J Alzheimers Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research.
Ezgi Tanriver-Ayder, Christel Faes, Tom van de Casteele, Sarah K McCann, Malcolm R Macleod

BMJ Open Sci· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to 'It is time for an empirically informed paradigm shift in animal research'.
Hanno Würbel, Bernhard Voelkl, Naomi S Altman, Anders Forsman, Wolfgang Forstmeier, Tom Van de Casteele

Nat Rev Neurosci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility of animal research in light of biological variation.
Bernhard Voelkl, Naomi S Altman, Anders Forsman, Wolfgang Forstmeier, Jessica Gurevitch, Tom Van de Casteele

Nat Rev Neurosci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Reproducibility of animal research in light of biological variation.
Bernhard Voelkl, Naomi S Altman, Anders Forsman, Wolfgang Forstmeier, Jessica Gurevitch, Tom Van de Casteele

Nat Rev Neurosci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals.
Jan Vollert, Esther Schenker, Malcolm Macleod, Anton Bespalov, Hanno Wuerbel, Tom van de Casteele

BMJ Open Sci· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.
Marc Vandermeeren, Marianne Borgers, Kristof Van Kolen, Clara Theunis, Bruno Vasconcelos, Tom Van De Casteele

J Alzheimers Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-β-induced pathology.
Jelle Praet, Nikolay V Manyakov, Leacky Muchene, Zhenhua Mai, Vasilis Terzopoulos, Tom Van De Casteele

Alzheimers Res Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.
Thomas N Kakuda, Tom Van De Casteele, Romana Petrovic, Mark Neujens, Hiba Salih

Antivir Ther· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darunavir/cobicistat once daily for the treatment of HIV.
Thomas N Kakuda, Herta Crauwels, Magda Opsomer, Frank Tomaka, Tom van de Casteele

Expert Rev Anti Infect Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial.
Avy Violari, Rosa Bologna, Nagalingeswaran Kumarasamy, Jose Henrique Pilotto, Annemie Hendrickx, Tom Van de Casteele

Pediatr Infect Dis J· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
Karen Tashima, Gordon Crofoot, Frank L Tomaka, Thomas N Kakuda, Anne Brochot, Tom Van de Casteele

AIDS Res Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
Thomas N Kakuda, Anne Brochot, Frank L Tomaka, Tony Vangeneugden, Tom Van De Casteele

J Antimicrob Chemother· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
Thomas N Kakuda, Lorant Leopold, Maarten Timmers, Tom Van De Casteele, Vera Hillewaert

Int J Clin Pharmacol Ther· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Patricia Flynn, Svitlana Komar, Stephane Blanche, Carlo Giaquinto, Antoni Noguera-Julian, Tom Van de Casteele

Pediatr Infect Dis J· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
Thomas N Kakuda, Magda Opsomer, Maarten Timmers, Koen Iterbeke, Tom Van De Casteele

J Clin Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Erkki Lathouwers, Guy De La Rosa, Tom Van de Casteele, Benny Baeten, Frank Tomaka

Antivir Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.
Jan Fourie, Jason Flamm, Amalia Rodriguez-French, Don Kilby, Pere Domingo, Tom Van De Casteele

HIV Clin Trials· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Dénes Bánhegyi, Christine Katlama, Clóvis Arns da Cunha, Stefan Schneider, Anita Rachlis, Tom Van De Casteele

Curr HIV Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Erkki Lathouwers, Sandra De Meyer, Inge Dierynck, Tom Van de Casteele, Ludo Lavreys

Antivir Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Inge Dierynck, Sandra De Meyer, Erkki Lathouwers, Carline Vanden Abeele, Tom Van De Casteele

Antivir Ther· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Pedro Cahn, Jan Fourie, Beatriz Grinsztejn, Sally Hodder, Jean-Michel Molina, Tom Van De Casteele

AIDS· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis